The Medicines Company (MDCO), Merck & Co., Inc. (MRK), Baxter International Inc. (BAX): Three Reasons to Like This Critical Care Company

Page 1 of 2

The Medicines Company (NASDAQ:MDCO) is a mid-cap value stock that jumped by 21% in the last 12 months, trading at a 52-week price range of $20.04-$37.40. This is backed by strong performance and significant sales growth in marketed products such as anticoagulants. Essentially, the company provides medical solutions for the treatment of critical care patients in hospitals. I consider this an investment-grade company based on the following factors:

Solid portfolio with wide range of products and product candidates

Opportunity in highly competitive critical care and anticoagulant markets

Sales growth driving positive performance

The Medicines Company

Diversified portfolio
The company has three marketed products and five in different development stages. Importantly, all of them are focused on critical care therapeutics, which creates technology depth for the company. The marketed products in the U.S. include Angiomax, Cleviprex, and Argatroban.

: Angiomax injection, an anticoagulant agent, is used to prevent the formation of blood clots that lead to heart attack or stroke.

: Used as an anticoagulant in adult patients.

: Indicated for the reduction of blood pressure when oral therapy is not feasible.

Moreover, the pipeline includes a variety of product candidates. Of them, three products — cangrelor, oritavancin and MDCO-157 — are in advanced stages, and two — MDCO-2010 and MDCO-216 — are in early stages of development. The company also has a portfolio of generic products used for acute care. In addition, it co-partners with AstraZeneca to market the oral antiplatelet drug Brilinta in the U.S. and with Bristol-Myers Squibb for Recothrom in the global market. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding.

Opportunity in anticoagulant and critical care therapeutics markets
More than 5 million patients are admitted to American intensive care units annually, primarily for critical medical conditions including respiratory failure, postoperative management, stroke and heart failure. Increasingly, infants and the older population are getting admitted. According to GBI Research estimates, the overall critical care therapeutics market value is expected to grow at a compounded annual growth rate of 5% to reach $3.2 billion in 2019. The growth is largely driven by increasing demand of existing products, and approval and launches of new products.

The anticoagulant therapies market is large, and competition is very intense due to the incidence and severity of cardiovascular diseases. There are a number of anticoagulant therapies currently available in the market. New products such as oral anticoagulants are also in many pipelines. MarketResearch also estimates that the U.S. anticoagulants market will grow from $7.06 billion in 2012 to $15.32 billion in 2019. The Medicines Company (NASDAQ:MDCO) focuses mostly on the U.S. market and generates more than 90% of revenues from the U.S. Assuming even a 2% market share for its candidate product Angiomax, market opportunity for the company in the anticoagulant market will be around $170-$200 million by 2015.

Position among peers
Angiomax competes primarily with Eli Lilly’s ReoPro and Integrilin from Merck & Co., Inc. (NYSE:MRK). Integrilin is a platelet aggregation inhibitor indicated for the treatment of acute coronary syndrome and percutaneous coronary intervention. The product is losing its sales quarterly, possibly due to advent of new drugs and generic products. It is expected to decrease further in coming quarters. In the second quarter of 2013, Merck & Co., Inc. (NYSE:MRK)’s sales were down by 7% to $11 billion, and adjusted net income also decreased by 24% to $2.5 billion, or $0.84 per share, compared to same period last year. I suspect that this trend will continue for the next quarter.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!